Gilead Sciences Inc (GILD) - News Archive

Gilead Sciences Advances HIV Prevention and Cancer Treatment: Promising Developments from Recent Trials and Strategic CollaborationsFOSTER CITY, Calif. In a significant week for Gilead Sciences, Inc. (NASDAQ: GILD), the...

In an ambitious stride towards boosting global health equity, Gilead Sciences, Inc. has recently announced the signing of non-exclusive, royalty-free voluntary licensing agreements with six generic pharmaceutical manufa...

In a most discerning announcement, the firms of Gilead Sciences, Inc. and Genesis Therapeutics, Inc. have entered into a significant and strategic collaboration aimed at the discovery and development of novel small mole...

Gilead Sciences: Advancements in Lung Cancer, Primary Biliary Cholangitis, and HIV Treatments Gilead Sciences, Inc. (Nasdaq: GILD) has recently demonstrated significant strides across various facets of pharmaceutical re...

In a significant development for patients suffering from primary biliary cholangitis (PBC), Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livde...

Gilead Sciences Advances Healthcare Solutions: Accelerated Approval of Livdelzi and Innovations in HIV Prevention FOSTER CITY, Calif. Gilead Sciences, Inc. (Nasdaq: GILD) has made significant strides in the landscape of...

Gilead Presents Cutting-Edge Research Data at AIDS 2024 ConferenceFOSTER CITY, Calif. Gilead Sciences, Inc. (Nasdaq: GILD), a global biopharmaceutical leader, has announced its major contributions to the 25th Internatio...

FOSTER CITY, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) Announces Promising Full Efficacy and Safety Results for LenacapavirGilead Sciences, Inc. has heralded new promises in HIV prevention with the latest full effic...

Gilead Sciences, Inc. (Nasdaq: GILD) and the Elton John AIDS Foundation (EJAF) have announced the extension of their RADIAN partnership for an additional five years, with an unwavering focus on tackling the intensifying...

Gilead Sciences Inc, a leading biopharmaceutical company, has been facing significant challenges in recent times. With the departure of its chief medical officer and underperformance compared to competitors in the marke...

Sophisticated Medical Advances: Gilead Sciences Displays Groundbreaking Research Across HIV, Lymphoma, and Hepatitis at 2024 ConferencesFOSTER CITY, Calif. Gilead Sciences, Inc. (Nasdaq: GILD), a renowned leader in biop...

Gilead Sciences Inc. has recently made groundbreaking strides in the field of HIV/AIDS treatment with the development of their latest therapy, Sunlenca. This article delves into the details of this new drug and its pote...

Breaking New Ground in HIV Prevention: Gilead s Lenacapavir Delivers 100% EfficacyGilead Sciences, Inc. (Nasdaq: GILD) has recently unveiled groundbreaking data from its Phase 3 PURPOSE 1 trial, showcasing the impressiv...

New Findings Highlight Benefits of Early Treatment with Yescarta and Promising Results for Gilead s Colorectal and Upper GI Cancer TreatmentsIn recent announcements, Gilead Sciences, in collaboration with its subsidiary...

Gilead Sciences, a leading biopharmaceutical company, has recently published new data in the New England Journal of Medicine (NEJM) showcasing the positive outcomes of their investigational drugs, bulevirtide and domvan...

Exploring the Efficacy of Targeted Therapies in Colorectal and Upper GI Cancers: An Analysis of Recent StudiesThe field of oncology has witnessed significant advancements in recent years, with targeted therapies playing...

Gilead and Arcus Announce Promising Results of Domvanalimab Plus Zimberelimab and Chemotherapy in Upper GI CancersFOSTER CITY, Calif. & HAYWARD, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc....

Gilead Sciences, Inc. and Arcus Biosciences, Inc. have recently announced longer-term efficacy and safety results from the Phase 2 EDGE-Gastric study, specifically focusing on Arm A1. These updated findings provide valu...

Gilead Sciences: Navigating Phase 3 Trials Amid Market Share DynamicsFOSTER CITY, Calif. Gilead Sciences, Inc. (Nasdaq: GILD) has been diligently working on its portfolio of oncology therapeutics, with recent attention...

In the field of pharmaceutical sciences, continuous research and development efforts are vital for advancing cancer treatments and improving patient outcomes. Gilead Sciences, Inc. recently provided an update on the Pha...